CLASS II ONGOING Device recall · Reported 1 Nov 2023 · FDA Enforcement Report

Embrace2- Indicated for use as an adjunct to seizure recalled

Empatica Srl is recalling Embrace2- Indicated for use as an adjunct to seizure monitoring of adults and children, distributed nationwide in the US. The recall was initiated on 13 Jul 2023 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesUDI-DI: (1) Flamingo Pink EM2-FP-S - 00853858006133; (2) Sky Blue EM2-SB-2 - 00853858006140; (3) Seoul Grey EM2-SG-S - 00853858006126; (4) Boston Blue EM2-BB-S - 00853858006119; (5) Milan Black EM2-MB-S - 00853858006102 Lot Numbers: G11/H11
Quantity recalled1360 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0159-2024
FDA event ID
93215
Recalling firm
Empatica Srl, Milan, N/A
Classification
Class II
Status
Ongoing
Recall initiated
13 Jul 2023
FDA classified
24 Oct 2023
Reported
1 Nov 2023
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Device Malfunction
Device type
Patient Monitors

Timeline

13 Jul 2023Recall initiated by company
24 Oct 2023Classified by FDA+103 days
1 Nov 2023Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

May have a battery life lasting less than the full 48 hours, requiring the device to be charged more frequently.

Device recalls are issued when a component, software or design fault could cause the device to fail or give wrong readings. Many are corrections applied in the field rather than physical returns.

Product as listed by the FDA

Embrace2- Indicated for use as an adjunct to seizure monitoring of adults and children age 6 and up in home or healthcare facilities during periods of rest. Models: (1) Flamingo Pink EM2-FP-S; (2) Sky Blue EM2-SB-2; (3) Seoul Grey EM2-SG-S; (4) Boston Blue EM2-BB-S; (5) Milan Black EM2-MB-S

Where it was distributed

Worldwide distribution - US Nationwide and the countries of Italy, Ireland, Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Germany, Finland, Netherlands, Poland, Sweden.

Nationwide

Questions about this recall

Is Embrace2- Indicated for use as an adjunct to seizure monitoring of adults and children recalled?

Yes. Empatica Srl recalled Embrace2- Indicated for use as an adjunct to seizure monitoring of adults and children on 13 Jul 2023. The recall is Class II and its status is Ongoing. Recall number Z-0159-2024.

Why was it recalled?

May have a battery life lasting less than the full 48 hours, requiring the device to be charged more frequently.

Which lots are affected?

UDI-DI: (1) Flamingo Pink EM2-FP-S - 00853858006133; (2) Sky Blue EM2-SB-2 - 00853858006140; (3) Seoul Grey EM2-SG-S - 00853858006126; (4) Boston Blue EM2-BB-S - 00853858006119; (5) Milan Black EM2-MB-S - 00853858006102 Lot Numbers: G11/H11

Where was it sold?

Worldwide distribution - US Nationwide and the countries of Italy, Ireland, Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Germany, Finland, Netherlands, Poland, Sweden.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other Patient Monitors recalls

All 1,012